Lenalidomide Drug Market, By Application, By Strength, By Distribution Channel, By Geography

PUBLISHED: March 12, 2024

PAGES: 164 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The lenalidomide drug market is estimated to be valued at USD 13.21 Bn in 2024 and is expected to reach USD 20.45 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 13.21 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	6.40%	2030/2031 Value Projection:	US$ 20.45 Bn

Lenalidomide Drug Market Share (%), By Region, 2024

Lenalidomideis an immunomodulatory drug used for the treatment of multiple myeloma and myelodysplastic syndromes. It works by modulating the immune system and inhibiting angiogenesis. Lenalidomide was first approved by the U.S. Food and Drug Administration in 2006 and since then has become a core drug in the treatment regimen for multiple myeloma. It is commonly used in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Lenalidomide continues to have a strong market position due to its efficacy and increasingly long duration of treatment as new lines of therapy emerge.

Market Dynamics:

The global Lenalidomide drug market growth is driven by the rising prevalence of multiple myeloma globally. According to 2024 estimates of American Cancer Society, a non-profit organization dedicated to eliminating cancer, in the U.S., approximately 35,780 new cases of myeloma will be diagnosed (19,520 in men and 16,260 in women), with an estimated 12,540 deaths (7,020 in males and 5,520 in women). An aging population and improved diagnosis and awareness are contributing to the increasing disease prevalence. Furthermore, the market has witnessed restraints from patent expirations of branded drugs and the introduction of generic competition. However, the key players are focusing on the expansion of Lenalidomide's indications to broader patient segments and line of therapies, which is opening new avenues of growth. Additionally, increasing research on drug combinations and next-gen treatments presents opportunities for market players to strengthen their market position.

Key Features of the Study:

This report provides an in-depth analysis of the global Lenalidomide drug market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Lenalidomide drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Cipla Inc., Apotex Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lotus, NATCO Pharma Limited, Sandoz Group AG, Aurobindo Pharma, Zydus Group, and Intas Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global Lenalidomide drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Lenalidomide drug market.

Detailed Segmentation:

Strength:
- 10 mg
- 20 mg
- 25 mg
- Others
Application:
- Multiple myeloma (MM)
- Transfusion-dependent anemia
- Mantle cell lymphoma (MCL)
- Others
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Reddy's Laboratories Ltd.
- Cipla Inc.
- Apotex Inc.
- Viatris Inc.
- Sun Pharmaceutical Industries Ltd.
- Lotus
- NATCO Pharma Limited
- Sandoz Group AG
- Aurobindo Pharma
- Zydus Group
- Intas Pharmaceuticals Ltd.

Product Code: CMI6750

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot By Application
- Market Snapshot By Strength
- Market Snapshot By Distribution Channel
- Market Snapshot By Region
- Market Scenario - Conservative, Likely, Opportunistic
Market Opportunity Map

3. Market Dynamics

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Pest Analysis
Porters Analysis
Technological Advancement
Merger, Acquisition and Collaboration Scenario
Recent Product Approvals
Company Market Share Analysis
Regulatory Scenario
Pricing Analysis
COVID-19 Impact Analysis
Epidemiology
Historical Roadmap of Approvals
Manufacturing Capacities
Distributors Landscape

4. Global Lenalidomide Drug Market, By Application, 2019 - 2031 (US$ Billion)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031
- Market Y-o-Y Growth Comparison (%), 2019 - 2031
- Segment Trends
Multiple myeloma (MM), 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Transfusion-dependent anemia, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Mantle cell lymphoma (MCL), 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Others, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)

5. Global Lenalidomide Drug Market, By Strength, 2019 - 2031 (US$ Billion)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031
- Market Y-o-Y Growth Comparison (%), 2019 - 2031
- Segment Trends
10 mg, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
20 mg, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
25 mg, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Others, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)

6. Global Lenalidomide Drug Market, By Distribution Channel, 2019 - 2031 (US$ Billion)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031
- Market Y-o-Y Growth Comparison (%), 2019 - 2031
- Segment Trends
Hospital Pharmacies, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Online Pharmacies, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)
Retail Pharmacies, 2019 - 2031 (US$ Billion)
- Introduction
- Market Size and Forecast, 2019 - 2031, (US$ Billion)

7. Global Lenalidomide Drug Market, By Region, 2019 - 2031 (US$ Billion)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, (US$ Billion)
- Market Y-o-Y Growth Comparison (%), 2024 - 2031, (US$ Billion)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest Of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
China
India
Japan
Australia
South Korea
ASEAN
Rest Of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
GCC
Israel
Rest Of The Middle East
Africa
- Introduction
- Market Size and Forecast, By Application, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Strength, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion)
- Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion)
South Africa
North Africa
Central Africa

8. Company Profiles - Global Lenalidomide Drug Market

Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product/Service Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategic Overview
Bristol-Myers Squibb Company
Dr. Reddy's Laboratories Ltd.
Cipla Inc.
Apotex Inc.
Viatris Inc.
Sun Pharmaceutical Industries Ltd.
Lotus
NATCO Pharma Limited
Sandoz Group AG
Aurobindo Pharma
Zydus Group
Intas Pharmaceuticals Ltd.